HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $10 price target.

May 14, 2024 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cocrystal Pharma receives a reiterated Buy rating and a maintained $10 price target from HC Wainwright & Co., indicating strong analyst confidence.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a maintained price target well above the current trading price suggest a strong bullish outlook for COCP, potentially leading to increased investor interest and a positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100